BioPharmX Corporation Files Registration Statement
Post# of 223
Posted On: 04/10/2015 12:12:12 AM
BioPharmX Corporation Files Registration Statement For Proposed Public Offering
MENLO PARK, Calif., April 9, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of its common stock. The number of shares to be offered by BioPharmX and the price range for the offering have not yet been determined.
The company intends to list its common stock on the NYSE MKT under the symbol "BPMX". BioPharmX expects to use the net proceeds it receives from the offering for research and development associated with the development of the company's product candidates, and research and development pipeline, marketing and advertising for the company's Violet™ iodine product, working capital, capital expenditures, and other general corporate purposes, including strategic hires.
CRT Capital Group LLC is acting as sole book-running manager for the offering. Feltl and Company and Newport Coast Securities, Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from: CRT Capital Group LLC, c/o Kirk Crecco, 262 Harbor Drive, Stamford, CT 06902, or by telephone at (203) 548-8008.
MENLO PARK, Calif., April 9, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of its common stock. The number of shares to be offered by BioPharmX and the price range for the offering have not yet been determined.
The company intends to list its common stock on the NYSE MKT under the symbol "BPMX". BioPharmX expects to use the net proceeds it receives from the offering for research and development associated with the development of the company's product candidates, and research and development pipeline, marketing and advertising for the company's Violet™ iodine product, working capital, capital expenditures, and other general corporate purposes, including strategic hires.
CRT Capital Group LLC is acting as sole book-running manager for the offering. Feltl and Company and Newport Coast Securities, Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from: CRT Capital Group LLC, c/o Kirk Crecco, 262 Harbor Drive, Stamford, CT 06902, or by telephone at (203) 548-8008.
(0)
(0)